Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.51 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023915 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2TRPV6MEN1KMT2A | |
| SCHEMBL5023886 | 0.94 | HCRTR2 (0.45) | HCRTR1HCRTR2TRPV6MEN1KMT2A | |
| SCHEMBL5017752 | 0.94 | HCRTR2 (0.45) | HCRTR1HCRTR2TRPV6MEN1KMT2A | |
| SCHEMBL5017748 | 0.94 | HCRTR2 (0.45) | HCRTR1HCRTR2TRPV6MEN1KMT2A | |
| SCHEMBL14285587 | 0.83 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL25235970 | 0.79 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL14309091 | 0.76 | HCRTR2 (0.45) | HCRTR1HCRTR2MEN1KMT2ATDP1 | |
| SCHEMBL4574026 | 0.76 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL4574022 | 0.76 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL14285579 | 0.75 | HCRTR2 (0.41) | HCRTR1HCRTR2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314940-B2 | For therapy and prophylaxis of neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7314940-B2 | For therapy and prophylaxis of neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1373269-B1 | JUN KINASE INHIBITORS | EISAI CO LTD (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20040235864-A1 | Jun kinase inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235864-A1 | Jun kinase inhibitors | NFKBIA, JUN, AIFM1 | HCRTR1 1938/4885HCRTR2 1735/4885TRPV6 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.